Active Ingredient History
Dantrolene is a drug which was approved by FDA for the treatment of chronic spasticity and malignant hyperthermia (a rare life-threatening clinical syndrome). Dantrolene effect was shown both in vivo and in vitro and proved to be mediated by interaction with Ryanodine receptor 1. The drug has a potential for hepatotoxicity and should be used as indicated in the label. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Malignant Hyperthermia (approved 1974)
Muscle Spasticity (approved 1974)
Angina Pectoris (Phase 3)
Angina, Stable (Phase 1)
Ataxia (Phase 1/Phase 2)
Diabetes Mellitus (Phase 1/Phase 2)
Fever (Phase 2/Phase 3)
Healthy Volunteers (Phase 1)
Heat Stroke (Phase 2)
Hemorrhage (Phase 1/Phase 2)
Hyperthermia (Phase 2/Phase 3)
Optic Atrophy (Phase 1/Phase 2)
Spinal Injuries (Phase 2)
Stroke (Phase 3)
Subarachnoid Hemorrhage (Phase 1/Phase 2)
Tachycardia, Ventricular (Early Phase 1)
Vasospasm, Intracranial (Phase 1/Phase 2)
Wolfram Syndrome (Phase 1/Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue